По вашему запросу найдено документов: 287

Страница 1 из 29

THE OFF-LABEL USE OF DRUGS FOR PARENTERAL NUTRITION AS A SOLVENT OF SUBSTANCES SLIGHTLY SOLUBLE IN WATER IN PHARMACOLOGICAL RESEARCH
Urakov, A.L., Mustafin, I.G., Samorodov, A.V., Kamilov, F.K., Khaliullin, F.A. (2017)
THE OFF-LABEL USE OF DRUGS FOR PARENTERAL NUTRITION AS A SOLVENT OF SUBSTANCES SLIGHTLY SOLUBLE
THE IMMUNE RESPONSE MEDIATOR GENES POLYMORPHIC VARIANTS AS PREDICTORS OF THE ETANERCEPT EFFICACY IN JUVENILE IDIOPATHIC ARTHRITIS
Nazarova, L.S., Danilko, K.V., Malievsky, V.A., Bakirov, A.B., Viktorova, T.V. (2018)
1800795, rs1800872, rs3087243, rs755622 rs28362491, rs2240336, rs2476601) with the etanercept efficacy
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial
Burtness, B., Haddad, R., Dinis, J., Trigo, J., Yokota, T, De Souza Viana, L., Romanov, I., Vermorken, J., Bourhis, J., Tahara, M., Martins Segalla, J.G., Psyrri, A., Vasilevskaya, I., Nangia, C.S., Chaves-Conde, M., Kiyota, N., Homma, A., Holeckova, P., Del Campo, J.M., Asarawala, N., Nicolau, U.R., Rauch, D., Even, C., Wang, B., Gibson, N., Ehrnrooth, E., Harrington, K., Cohen, E.E.W. (2019)
has shown efficacy in recurrent or metastatic HNSCC. Objective: To assess whether afatinib therapy
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III OR IV HODGKIN'S LYMPHOMA
CONNORS, J.M., SAVAGE, K.J, JURCZAK, W, LECH-MARANDA, E., SMOLEWSKI, P, WALEWSKI, J, STRAUS, D.J., YOUNES, A., ANSELL, S.M., KIM, W.S., GALLAMINI, A., ALEKSEEV, S., ILLÉS, A., ROSTA, A., PICARDI, M., ZINZANI, P.L., OKI, Y., FELDMAN, T., BARTLETT, N.L., CHEN, R., RAMCHANDREN, R., CUNNINGHAM, D., RADFORD, J., JOSEPHSON, N.C., SONG, E., SACHS, J., JOLIN, H.A., HUEBNER, D., LIU, R., LIPATOV, O.N. (2018)
for relapsed and refractory Hodgkin’s lymphoma. METHODS We conducted an open-label, multicenter, randomized
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study
Lomakin, NV, Bakirov, BA, Protsenko, DN, Mazurov, VI, Musaev, GH, Moiseeva, OM, Pasechnik, ES, Popov, VV, Smolyarchuk, EA, Gordeev, IG, Gilyarov, MY, Fomina, DS, Seleznev, AI, Linkova, YN, Dokukina, EA, Eremeeva, AV, Pukhtinskaia, PS, Morozova, MA, Zinkina-Orikhan, AV, Lutckii, AA (2021)
trial was to evaluate the efficacy and safety of IL-6 receptor inhibitor levilimab (LVL) in subjects
EFFICACY AND SAFETY OF INSULIN GLARGINE 300 UNITS/ML (GLA-300) VERSUS INSULIN GLARGINE 100 UNITS/ML (GLA-100) IN CHILDREN AND ADOLESCENTS (6-17 YEARS) WITH TYPE 1 DIABETES: RESULTS OF THE EDITION JUNIOR RANDOMIZED CONTROLLED TRIAL
DANNE, T., TAMBORLANE, W.V., MALIEVSKY, O.A., FRANCO, D.R., KAWAMURA, T., DEMISSIE, M., NIEMOELLER, E., GOYEAU, H., WARDECKI, M., BATTELINO, T. (2020)
OBJECTIVE To compare efficacy and safety of insulin glargine 300 units/mL (Gla-300) and 100 units
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
Deal, C, Steelman, J, Vlachopapadopoulou, E, Stawerska, R, Silverman, LA;, Phillip, M, Kim, HS, Ko, CW, Malievskiy, O, Cara, JF, Roland, CL, Taylor, CT, Valluri, SR, Wajnrajch, MP, Pastrak, A, Miller, BS (2022)
the efficacy and safety of once-weekly somatrogon with once-daily somatropin in prepubertal children with GHD
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
Maniatis, AK;, Casella, SJ;, Nadgir, UM;, Hofman, PL;, Saenger, P;, Chertock, ED;, Aghajanova, EM;, Korpal-Szczyrska, M;, Vlachopapadopoulou, E;, Malievskiy, O;, Chaychenko, T;, Cappa, M;, Song, WJ;, Mao, M;, Mygind, PH;, Smith, AR;, Chessler, S;, Komirenko, AS;, Beckert, M;, Aimee, D Shu, Paul, S Thornton (2022)
Purpose: The objectives of the ongoing, Phase 3, open-label extension trial enliGHten are to assess
EFFICACY OF A PLANT-BASED DENTAL GEL FOR CHRONIC SIMPLE MARGINAL GINGIVITIS: A CLINICAL TRIAL
Isaeva, A., Averyanov, S., Iskhakov, I., Gulyaeva, O., Gileva, O., Kiniabaev, T. (2020)
as part of complex therapy, while in the control group (22 patients) the Cholisal gel was used. The data
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis
Ruperto, N, Brunner, HI, Pacheco-Tena, C, Louw, I, Vega-Cornejo, G, Spindler, AJ, Kingsbury, DJ, Schmeling, H, Borzutzky, A, Cuttica, R, Inman, CJ, Malievskiy, V, Scott, C, Keltsev, V, Terreri, MT, Viola, DO, Xavier, RM, Fernandes, TAP, Velazquez, MDM, Henrickson, M, Clark, MB, Bensley, KA, Li, XM, Lo, KH, Leu, JH, Hsu, CH, Hsia, EC, Xu, ZH, Martini, A, Lovell, DJ, Group Authors:Pediat Rheumatology Collaborative (Pediat Rheumatology Collaborative), Paediat Rheumatology Int Trials Or (Paediat Rheumatology Int Trials Or) (2021)
Objectives To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab

Страница 1 из 29

Google Scholar
OpenDoar

Фасеты

Авторы
Ключевые слова
Год